Journal of Clinical Oncology
Articles in this Issue
Effect of chemoradiation followed by surgery on outcomes compared to definitive chemoradiation in locally advanced esophageal squamous cell carcinoma: A single-center experience.
e16129 Background: Esophageal squamous cell carcinoma (ESCC) constitutes a major health problem in eastern Turkey, which is a part of a high-incidence are...
Enhancing diversity in oncology trials: Key strategies from the ACORI community oncology inclusive clinical trial design summit.
e23027 Background: Oncology clinical trials often lack ethnic and regional diversity , limiting the generalizability of findings across real-world patient...
Clinico-radiographic predictors of overall survival in stage II-III pancreatic cancer.
e16457 Background: Patients with inoperable stage II-III pancreatic cancer commonly undergo sequential stereotactic body radiation therapy (SBRT) and chem...
Impact of body weight and body composition on survival and toxicities in patients receiving CDK4/6 inhibitors for ER+/HER2- metastatic breast cancer.
1087 Background: Body composition influences treatment outcomes and adverse events in many oncologic conditions including metastatic breast cancer (mBC)....
The impact of lymph node dissection on the prognosis of patients with intrahepatic cholangiocarcinoma.
e16313 Background: Intrahepatic cholangiocarcinoma (ICC) makes up ~20% of liver cancers. Radical resection is the sole potential cure, with lymph node met...
Trends in photon and proton radiotherapy populations in pediatric patients: A single institutional experience.
e13517 Background: The Children’s Hospital of Los Angeles (CHLA) offers advanced forms of photon radiation therapy to pediatric cancer patients; however,...
Dual-omic analysis to reveal gene regulatory network of immune landscape in childhood solid tumors and implications for immunotherapy.
e14570 Background: Immune checkpoint blockades (ICBs) showed little efficacy in pediatric solid tumors. The reconfiguration of gene regulation in cancers...
Socioeconomic disparities in survival outcomes among children with non-metastatic Ewing sarcoma treated on upfront Children’s Oncology Group clinical trials.
10041 Background: Poverty is emerging as an adverse risk factor for relapse and death across many pediatric cancers. Socioeconomic disparities have not be...
Lung cancer diagnosis rates (LCDR) in lung cancer screening (LCS) and incidental pulmonary nodule (IPN) cohorts in the Mississippi Delta.
8002 Background: The LCDR in the CT screened cohort in the National Lung Screening Trial (NLST) was 1.1% over a median of 6.5 years follow up. We evaluate...
Association between environmental burden and cancer incidence rates across population subgroups in the United States (US).
11009 Background: With more than 2 million projected new cancer diagnoses in 2025 in the US alone, many studies have linked environmental pollutants to ca...
A phase Ib study to assess the safety and efficacy of autologous tumor infiltrating lymphocytes (lifileucel) with adjuvant pembrolizumab (PEMBRO) for treatment of immunotherapy naïve patients with high-risk clinical stage IIIb-d resectable melanoma (MEL).
TPS9611 Background: Despite significant advances in the treatment (Tx) of stage III MEL, there remains a high risk of recurrence after surgical resection....
Cervical cancer screening updates across Paraguay: Evaluation of the national cancer control program (PRONAC) initiative using HPV testing during 2024.
e17505 Background: Cervical cancer is one of the most prevalent and deadly neoplasms in Paraguay. Globocan 2022 reported 1,115 new cases, accounting for 8...
Multiomics profiling for prediction of immunotherapy response in advanced pleural mesothelioma: Sub-study of the NIPU trial.
8086 Background: The combination of ipilimumab and nivolumab (IPI/NIVO) is a standard treatment for unresectable pleural mesothelioma. However, the object...
KEYNOTE-859: 4.5-year median follow-up of pembrolizumab plus chemotherapy for previously untreated advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.
4036 Background: In the phase 3KEYNOTE-859 study (NCT03675737), first-linepembrolizumab (pembro) + chemotherapy (chemo) co...
Association of SMOX gene expression with immune checkpoint therapy response in patients with non-small cell lung cancer.
e14559 Background: SMOX is a gene encoding spermine oxidase which is an important enzyme in the catabolism of polyamines. It is associated with tumor prog...
New-onset osteopenia/osteoporosis among long-term survivors of breast cancer: Role of hormone therapies and metabolic risk factors.
12046 Background: Anti-cancer therapies (including aromatase inhibitors [AIs]) and metabolic risk factors are known to result in bone mineral density (BMD...
Comparison of intensity-modulated radiotherapy and 3D conformal radiotherapy in the treatment of esophageal carcinoma: A systematic review and meta-analysis.
e16001 Background: Esophageal carcinoma ranks among the top 10 malignancies in the world, contributing to high morbidity and mortality. With radiotherapy...
Spatial transcriptomic profiling from over 300 leiomyosarcoma samples.
11508 Background: Leiomyosarcoma (LMS) is a smooth muscle-derived tumor with significant heterogeneity and limited treatment options for recurrent/metasta...
Use of an in-silico clinical trial intelligence solution to predict outcomes of tinengotinib, a potent multi-kinase small molecule FGFR inhibitor in patients with cholangiocarcinoma, based on the molecular matching score.
e15190 Background: Cancer genomic diversity, with a median of ~5 pathogenic molecular alterations per tumor, presents a challenge in predicting clinical o...
Preliminary results of anlotinib and penpulimab (anti-PD1) combined with GEMOX in first-line treatment of advanced biliary tract cancer: A single-center, single-arm exploratory study.
e16195 Background: Biliary tract cancer (BTC) is a rare, yet highly aggressive malignancy, comprising approximately 3% of all gastrointestinal cancers. Th...
A phase II study of lenvatinib plus pembrolizumab in patients with recurrent/metastatic salivary gland cancers.
6103 Background: Recurrent/metastatic (R/M) salivary gland cancers (SGCs) are rare diseases without standard therapies. Based on the hypothesis that VEGFR...
CONUT score as a predictor of venous thromboembolism in high-risk hospitalized cancer patients based on Caprini risk assessment model.
e24013 Background: Venous thromboembolism (VTE) is a major cause of morbidity and mortality in cancer patients. However, current predictive tools, such as...
A phase I study of AFNT-211, autologous CD4 <sup>+</sup> and CD8 <sup>+</sup> T cells engineered to express a high avidity HLA-A*11:01-restricted, KRAS G12V-specific transgenic TCR; CD8α/β coreceptor; and FAS-41BB switch receptor in patients with advanced or metastatic solid tumors.
TPS2678 Background: Activating mutations in KRAS (including KRAS G12V) are well-described oncogenic drivers in solid tumors, conferring poor prognosis to...
Patient preference for first-line treatments of ALK-positive metastatic non-small cell lung cancer: A discrete choice experiment.
11103 Background: For patients with ALK-positive metastatic NSCLC, targeted therapy with ALK inhibitors is a recommended first-line treatment. The develop...
Impact of insurance coverage on diagnosis and surgical treatment of gastric malignancies in urban populations.
e13783 Background: This study aims to investigate the influence of insurance coverage on the diagnosis and surgical management of gastric malignancies in...